Startups & VC

Biotech Startup M&A Is Reliably Delivering Some Big Exits

32 sec read12 views0 listens

Biotech startups have seen significant M&A activity over the past two years, with acquisitions totaling over $38 billion, highlighting steady exits despite lower-profile status compared to AI unicorns. Key deals include Eli Lilly's acquisition of Orna Therapeutics for up to $2.4 billion and Johnson & JohnsonG??s purchase of Halda Therapeutics for $3.05 billion, indicating a robust market for biotech acquisitions. However, the sector faces reduced funding shares and weak IPO activity, suggesting a stable but not booming environment for biotech startups.

Read the full article at Crunchbase News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Legal & Policy2 days ago32 sec read

A Tribute, A Tactic, Or An Appellate Issue?

A prosecutor's use of hair bows in the Lindsay Clancy murder trial is being scrutinized as a potential tactic that could lead to an appeal, rather than relying solely on evidence. Separately, private equity firm Charlesbank Capital Partners is report...

Ali Nemati

EntertainmentAug 1528 sec read

Selena Gomez forcefully responds to fraud lawsuit against her mental health brand

Selena Gomez has strongly rejected a fraud lawsuit against her mental health brand Wondermind, asserting that the claims are without merit. The lawsuit alleges false representation regarding the company's capabilities and leadership, suggesting it wa...

Ali Nemati

Biotech & PharmaJul 2226 sec read

Transcripta Bio Raises $24M for AI-Driven Neurological Disease Therapies

Transcripta Bio, an AI-driven drug discovery startup, has raised $24 million to advance its neurological disease therapies. The funding will support clinical preparations for conditions like autism spectrum disorder and muscular dystrophy, leveraging...

Ali Nemati